FDA Widens Olympus Import Alert to GI Scopes

Q: What did FDA do on 20 October 2026?

FDA updated Import Alert 89-04, which covers select Olympus medical devices manufactured at the company's Aizu, Japan facility, adding two device categories — ingestible telemetric GI capsule-imaging systems (the Endocapsule line) and enteroscopes (small-intestine videoscopes). Trade press describes the addition as five more models, bringing the alert's total to 63.

Q: Does this affect devices already in US hospitals?

No. Import Alert 89-04 lets FDA detain shipments of the listed models at the US border without physical examination; it does not require hospitals or clinics to stop using devices already in service, and it is not a recall.

Q: How does this connect to Olympus's October 7 warning letter?

FDA sent Olympus a warning letter dated 7 October 2026, disclosed by the company on October 13, over inadequate corrective and preventive action in response to quality-management-system findings logged on 2025 inspections of six Olympus sites in Japan, the US and Europe — reported separately by Regulatory News. The October 20 import-alert update followed less than two weeks later and covers different product lines than the warning letter's inspection findings; FDA's own materials tie it to the same underlying manufacturing-quality concerns at Aizu.

Q: What was Import Alert 89-04 before this update?

FDA first issued Import Alert 89-04 on 24 June 2025, covering roughly 58 Olympus models manufactured at Aizu across four device categories: ureteroscopes, bronchoscopes, laparoscopes and automated endoscope reprocessors. The October 2026 update is the first expansion of that alert to add new device categories rather than new models within the original four.

FDA Widens Olympus Import Alert to GI Scopes

FDA updated Import Alert 89-04 on 20 October 2026, adding Olympus’s ingestible capsule-endoscopy system and a small-intestine videoscope to the list of Japan-made devices it will detain at the border — five more models, two weeks after a warning letter over how the company responded to findings at six of its plants.

Connor GriggsFounder & Editor-in-ChiefOctober 26, 2026 (6 min read)

FDA widened its import alert on Olympus's Japan-made endoscopy devices on 20 October 2026, adding the company's ingestible capsule-endoscopy system and a small-intestine videoscope to a list that already blocked dozens of ureteroscope, bronchoscope, laparoscope and reprocessor models from entering the United States. The update came thirteen days after FDA sent Olympus a warning letter over how the company handled corrective action on earlier inspection findings at six of its plants — a separate action Regulatory News reported on October 16.

In brief

FDA updated Import Alert 89-04 on 20 October 2026, adding Olympus's Endocapsule ingestible GI capsule-imaging line and an enteroscope (small-intestine videoscope) — five more models, per trade reporting, bringing the alert's total to roughly 63.
The alert covers devices manufactured at Olympus's Aizu, Japan facility; FDA detains listed models at the border without physical examination rather than ordering a recall.
The original alert issued 24 June 2025, covering about 58 models across four categories: ureteroscopes, bronchoscopes, laparoscopes and automated endoscope reprocessors.
The update follows a separate FDA warning letter dated 7 October 2026, disclosed by Olympus on October 13, over its response to quality-management-system findings at six manufacturing sites in Japan, the US and Europe — Olympus's fourth warning letter since 2022.
Devices already in US hospitals and clinics are not affected; the alert blocks further import, not continued clinical use.

What changed on October 20

FDA's Center for Devices and Radiological Health updates import alerts by adding or removing entries from a standing list rather than issuing an entirely new alert each time, and that is what happened here: Import Alert 89-04, first issued in June 2025 against a defined set of Aizu-manufactured Olympus endoscopy devices, gained two new device categories on October 20, 2026. Trade publications covering the update — MDDI, Medical Daily and MedTech Dive among them — describe the addition as Olympus's Endocapsule ingestible telemetric capsule-imaging system and an enteroscope, a videoscope built for the small intestine, adding roughly five models and pushing the alert's running total to about 63. FDA's own notice takes the form of an updated “Letter to Health Care Providers,” the same mechanism it used for the original 2025 alert.

What an import alert actually does

An import alert is not a recall and does not reach devices already placed in US hospitals or clinics. It instructs FDA field staff to detain shipments of the named models at the border “without physical examination” — the agency's standard import-alert language — on the basis that the listed products appear to violate US manufacturing requirements. For Olympus, that means new units of the affected models manufactured at Aizu cannot enter the US supply chain unless the company demonstrates to FDA's satisfaction that the specific shipment, or the underlying manufacturing process, meets requirements. It is a border-control mechanism tied to manufacturing-quality concerns at a specific facility, not a judgment on the safety of devices already in the field.

The warning letter it follows

The update lands inside a two-week stretch of FDA scrutiny of Olympus's quality systems. On October 7, 2026, FDA sent the company a warning letter — its fourth since 2022, Olympus disclosed on October 13 — faulting how Olympus responded to quality-management-system findings FDA had already logged during 2025 inspections of six manufacturing sites across Japan, the United States and Europe. Regulatory News covered that letter separately on October 16. The warning letter does not itself restrict manufacturing, sales or distribution, and FDA had not yet posted it to its public warning-letter database as of initial reporting. The October 20 import-alert update is a distinct action with its own legal basis — the Aizu facility's manufacturing record under the Federal Food, Drug, and Cosmetic Act — but it arrives against the same backdrop of sustained FDA attention to Olympus's quality systems, and sponsors tracking the company's regulatory standing should treat the two as related signals rather than isolated events.

What this means operationally

Hospitals and GI practices: devices already in service are unaffected; this is an import control on new shipments, not a field action. Procurement teams expecting new Endocapsule or enteroscope units manufactured at Aizu should confirm supply timelines with Olympus directly rather than assume continuity.
Competitors and distributors: an import alert covering two more GI device categories widens the window for competing capsule-endoscopy and enteroscopy makers to compete for US hospital contracts while the affected models are blocked from new import.
RA/QA teams at other device makers with Japan-manufactured product: the escalation — from a four-category import alert in June 2025, to a warning letter over CAPA adequacy in October 2026, to a same-month expansion covering two more categories — illustrates how FDA can widen an import alert's scope without a new inspection of the added product lines, based on its broader view of a facility's quality system.
Olympus: the company's public response to the October 7 warning letter said corrective and preventive action work was already underway and that a formal response would follow within 15 business days of the letter, per Japanese trade press cited in Regulatory News's earlier report; Regulatory News found no Olympus statement specific to the October 20 import-alert update at the time of writing.

What is not yet settled

FDA's updated letter does not state when, or whether, the newly added device categories will be removed from the alert, and the agency's public import-alert pages do not carry a timeline for Olympus's broader corrective-action work across the six sites named in the October 7 warning letter. Regulatory News could not independently confirm, from the sourcing available, a precise FDA reference number for the October 20 update or a complete list of the five added model numbers; readers verifying specific device eligibility for import should consult FDA's own updated letter to health care providers directly.

Frequently asked questions

What did FDA do on 20 October 2026?

Updated Import Alert 89-04 to add two Olympus device categories — the Endocapsule ingestible GI capsule-imaging system and an enteroscope (small-intestine videoscope) — roughly five more models, bringing the alert's total to about 63.

Does this affect devices already in US hospitals?

No. It blocks new imports of the listed models at the border; it is not a recall and does not require hospitals to stop using devices already in service.

How does this connect to Olympus's October 7 warning letter?

The warning letter, disclosed October 13, concerned CAPA adequacy at six manufacturing sites. The import-alert update followed less than two weeks later and covers different product lines, but both reflect sustained FDA attention to Olympus's quality systems.

What was Import Alert 89-04 before this update?

Issued 24 June 2025, covering about 58 Aizu-manufactured models across four categories: ureteroscopes, bronchoscopes, laparoscopes and automated endoscope reprocessors.

Sources & further reading

FDA, “Update: Import Alert for Certain Olympus Medical Devices Manufactured in Japan — Letter to Health Care Providers,” 20 October 2026. fda.gov
FDA, the original Import Alert 89-04 letter to health care providers, 24 June 2025. fda.gov
MDDI, “Another Import Alert for Olympus,” 21 October 2026. mddionline.com
Medical Daily, “Olympus Capsule Endoscope Set and Small-Intestine Scope Join FDA Import Alert, but Hospitals Can Keep Using Current Devices.” medicaldaily.com
MedTech Dive, “Olympus responds to FDA endoscopy import alert.” medtechdive.com
Citeline / Medtech Insight, “FDA Widens Olympus Import Alert To GI Products After Six-Site Warning Letter.” citeline.com

Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.